Ascendis Pharma A/S (ASND)

Ascendis Pharma A/S is trading at $252.53, up 2.07% on the session. The 50 day average sits at $246.11 and the 200 day at $n/a, which puts the stock in a mixed technical position. RSI is at 46.1, which reads as neutral, and MACD is bearish crossover. Volume is above average.

The nearest support is around $239.56 with resistance near $249.96, so that band frames the current range. Average daily movement is roughly $8.47, or about 3.4% of the share price, which is what any stop placement has to allow for. The overall health score of 56 out of 100 combines a trend score of 68, momentum of 37 and a risk score of 63.

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.